PMC:7239011 / 4255-5403 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"168","span":{"begin":151,"end":159},"obj":"Species"},{"id":"169","span":{"begin":165,"end":177},"obj":"Species"},{"id":"170","span":{"begin":255,"end":263},"obj":"Species"},{"id":"171","span":{"begin":282,"end":292},"obj":"Species"},{"id":"172","span":{"begin":799,"end":807},"obj":"Species"},{"id":"173","span":{"begin":911,"end":919},"obj":"Species"},{"id":"174","span":{"begin":936,"end":946},"obj":"Species"},{"id":"175","span":{"begin":1034,"end":1042},"obj":"Species"},{"id":"176","span":{"begin":217,"end":228},"obj":"Chemical"},{"id":"177","span":{"begin":269,"end":277},"obj":"Disease"},{"id":"178","span":{"begin":370,"end":380},"obj":"Disease"},{"id":"179","span":{"begin":384,"end":400},"obj":"Disease"},{"id":"180","span":{"begin":529,"end":539},"obj":"Disease"},{"id":"181","span":{"begin":597,"end":606},"obj":"Disease"},{"id":"182","span":{"begin":704,"end":719},"obj":"Disease"},{"id":"183","span":{"begin":759,"end":769},"obj":"Disease"},{"id":"184","span":{"begin":790,"end":798},"obj":"Disease"},{"id":"185","span":{"begin":998,"end":1007},"obj":"Disease"},{"id":"186","span":{"begin":1025,"end":1033},"obj":"Disease"},{"id":"187","span":{"begin":1109,"end":1117},"obj":"Disease"}],"attributes":[{"id":"A168","pred":"tao:has_database_id","subj":"168","obj":"Tax:9606"},{"id":"A169","pred":"tao:has_database_id","subj":"169","obj":"Tax:12637"},{"id":"A170","pred":"tao:has_database_id","subj":"170","obj":"Tax:9606"},{"id":"A171","pred":"tao:has_database_id","subj":"171","obj":"Tax:64320"},{"id":"A172","pred":"tao:has_database_id","subj":"172","obj":"Tax:9606"},{"id":"A173","pred":"tao:has_database_id","subj":"173","obj":"Tax:9606"},{"id":"A174","pred":"tao:has_database_id","subj":"174","obj":"Tax:64320"},{"id":"A175","pred":"tao:has_database_id","subj":"175","obj":"Tax:9606"},{"id":"A176","pred":"tao:has_database_id","subj":"176","obj":"MESH:D005732"},{"id":"A177","pred":"tao:has_database_id","subj":"177","obj":"MESH:C000657245"},{"id":"A178","pred":"tao:has_database_id","subj":"178","obj":"MESH:D009422"},{"id":"A179","pred":"tao:has_database_id","subj":"179","obj":"MESH:D001102"},{"id":"A180","pred":"tao:has_database_id","subj":"180","obj":"MESH:D020258"},{"id":"A181","pred":"tao:has_database_id","subj":"181","obj":"MESH:D007239"},{"id":"A182","pred":"tao:has_database_id","subj":"182","obj":"MESH:D001102"},{"id":"A183","pred":"tao:has_database_id","subj":"183","obj":"MESH:D020258"},{"id":"A184","pred":"tao:has_database_id","subj":"184","obj":"MESH:C000657245"},{"id":"A185","pred":"tao:has_database_id","subj":"185","obj":"MESH:D011014"},{"id":"A186","pred":"tao:has_database_id","subj":"186","obj":"MESH:C000657245"},{"id":"A187","pred":"tao:has_database_id","subj":"187","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The cross-immunity between viral antigens and peripheral nerve glycolipids have not been well-documented. Positive GD1a antibody was reported in a few patients with dengue virus-related GBS (Simon et al., 2016). Anti-ganglioside antibody was not found in patients with COVID-19 and Zika virus-related GBS (Cao-Lormeau et al., 2016). This has led to speculation that the neuropathy in viral infections-related GBS could be due to other autoantibodies that are not detected as yet or the viruses produced nerve damage due to other neurotoxic effects. However, there is paucity of evidence of direct infection of peripheral nerves by viruses from the pathological studies. Good response to immunotherapy in viral infection-related GBS is also against the direct neurotoxic effects of viruses. COVID-19 patients with AIDP responded better as compared to those with axonal variants of GBS; a difference also seen in patients with dengue and Zika virus-related GBS. Recently, a good clinical response in pneumonia has been seen in COVID-19 patients with plasma therapy. Does plasma therapy produce good recovery in COVID-19-related GBS is yet to be seen."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T20","span":{"begin":46,"end":62},"obj":"Body_part"},{"id":"T21","span":{"begin":63,"end":74},"obj":"Body_part"},{"id":"T22","span":{"begin":120,"end":128},"obj":"Body_part"},{"id":"T23","span":{"begin":217,"end":228},"obj":"Body_part"},{"id":"T24","span":{"begin":229,"end":237},"obj":"Body_part"},{"id":"T25","span":{"begin":503,"end":508},"obj":"Body_part"},{"id":"T26","span":{"begin":610,"end":627},"obj":"Body_part"},{"id":"T27","span":{"begin":1048,"end":1054},"obj":"Body_part"},{"id":"T28","span":{"begin":1069,"end":1075},"obj":"Body_part"}],"attributes":[{"id":"A20","pred":"fma_id","subj":"T20","obj":"http://purl.org/sig/ont/fma/fma65239"},{"id":"A21","pred":"fma_id","subj":"T21","obj":"http://purl.org/sig/ont/fma/fma82780"},{"id":"A22","pred":"fma_id","subj":"T22","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A23","pred":"fma_id","subj":"T23","obj":"http://purl.org/sig/ont/fma/fma82816"},{"id":"A24","pred":"fma_id","subj":"T24","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A25","pred":"fma_id","subj":"T25","obj":"http://purl.org/sig/ont/fma/fma65132"},{"id":"A26","pred":"fma_id","subj":"T26","obj":"http://purl.org/sig/ont/fma/fma65239"},{"id":"A27","pred":"fma_id","subj":"T27","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A28","pred":"fma_id","subj":"T28","obj":"http://purl.org/sig/ont/fma/fma62970"}],"text":"The cross-immunity between viral antigens and peripheral nerve glycolipids have not been well-documented. Positive GD1a antibody was reported in a few patients with dengue virus-related GBS (Simon et al., 2016). Anti-ganglioside antibody was not found in patients with COVID-19 and Zika virus-related GBS (Cao-Lormeau et al., 2016). This has led to speculation that the neuropathy in viral infections-related GBS could be due to other autoantibodies that are not detected as yet or the viruses produced nerve damage due to other neurotoxic effects. However, there is paucity of evidence of direct infection of peripheral nerves by viruses from the pathological studies. Good response to immunotherapy in viral infection-related GBS is also against the direct neurotoxic effects of viruses. COVID-19 patients with AIDP responded better as compared to those with axonal variants of GBS; a difference also seen in patients with dengue and Zika virus-related GBS. Recently, a good clinical response in pneumonia has been seen in COVID-19 patients with plasma therapy. Does plasma therapy produce good recovery in COVID-19-related GBS is yet to be seen."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T12","span":{"begin":57,"end":62},"obj":"Body_part"},{"id":"T13","span":{"begin":503,"end":508},"obj":"Body_part"}],"attributes":[{"id":"A12","pred":"uberon_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/UBERON_0001021"},{"id":"A13","pred":"uberon_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/UBERON_0001021"}],"text":"The cross-immunity between viral antigens and peripheral nerve glycolipids have not been well-documented. Positive GD1a antibody was reported in a few patients with dengue virus-related GBS (Simon et al., 2016). Anti-ganglioside antibody was not found in patients with COVID-19 and Zika virus-related GBS (Cao-Lormeau et al., 2016). This has led to speculation that the neuropathy in viral infections-related GBS could be due to other autoantibodies that are not detected as yet or the viruses produced nerve damage due to other neurotoxic effects. However, there is paucity of evidence of direct infection of peripheral nerves by viruses from the pathological studies. Good response to immunotherapy in viral infection-related GBS is also against the direct neurotoxic effects of viruses. COVID-19 patients with AIDP responded better as compared to those with axonal variants of GBS; a difference also seen in patients with dengue and Zika virus-related GBS. Recently, a good clinical response in pneumonia has been seen in COVID-19 patients with plasma therapy. Does plasma therapy produce good recovery in COVID-19-related GBS is yet to be seen."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T31","span":{"begin":370,"end":380},"obj":"Phenotype"},{"id":"T32","span":{"begin":998,"end":1007},"obj":"Phenotype"}],"attributes":[{"id":"A31","pred":"hp_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/HP_0009830"},{"id":"A32","pred":"hp_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/HP_0002090"}],"text":"The cross-immunity between viral antigens and peripheral nerve glycolipids have not been well-documented. Positive GD1a antibody was reported in a few patients with dengue virus-related GBS (Simon et al., 2016). Anti-ganglioside antibody was not found in patients with COVID-19 and Zika virus-related GBS (Cao-Lormeau et al., 2016). This has led to speculation that the neuropathy in viral infections-related GBS could be due to other autoantibodies that are not detected as yet or the viruses produced nerve damage due to other neurotoxic effects. However, there is paucity of evidence of direct infection of peripheral nerves by viruses from the pathological studies. Good response to immunotherapy in viral infection-related GBS is also against the direct neurotoxic effects of viruses. COVID-19 patients with AIDP responded better as compared to those with axonal variants of GBS; a difference also seen in patients with dengue and Zika virus-related GBS. Recently, a good clinical response in pneumonia has been seen in COVID-19 patients with plasma therapy. Does plasma therapy produce good recovery in COVID-19-related GBS is yet to be seen."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T74","span":{"begin":165,"end":171},"obj":"Disease"},{"id":"T75","span":{"begin":186,"end":189},"obj":"Disease"},{"id":"T76","span":{"begin":269,"end":277},"obj":"Disease"},{"id":"T77","span":{"begin":282,"end":286},"obj":"Disease"},{"id":"T78","span":{"begin":301,"end":304},"obj":"Disease"},{"id":"T79","span":{"begin":370,"end":380},"obj":"Disease"},{"id":"T80","span":{"begin":384,"end":400},"obj":"Disease"},{"id":"T81","span":{"begin":409,"end":412},"obj":"Disease"},{"id":"T82","span":{"begin":597,"end":606},"obj":"Disease"},{"id":"T83","span":{"begin":704,"end":719},"obj":"Disease"},{"id":"T84","span":{"begin":710,"end":719},"obj":"Disease"},{"id":"T85","span":{"begin":728,"end":731},"obj":"Disease"},{"id":"T86","span":{"begin":790,"end":798},"obj":"Disease"},{"id":"T87","span":{"begin":813,"end":817},"obj":"Disease"},{"id":"T88","span":{"begin":868,"end":883},"obj":"Disease"},{"id":"T89","span":{"begin":880,"end":883},"obj":"Disease"},{"id":"T90","span":{"begin":925,"end":931},"obj":"Disease"},{"id":"T91","span":{"begin":936,"end":940},"obj":"Disease"},{"id":"T92","span":{"begin":955,"end":958},"obj":"Disease"},{"id":"T93","span":{"begin":998,"end":1007},"obj":"Disease"},{"id":"T94","span":{"begin":1025,"end":1033},"obj":"Disease"},{"id":"T95","span":{"begin":1109,"end":1117},"obj":"Disease"},{"id":"T96","span":{"begin":1126,"end":1129},"obj":"Disease"}],"attributes":[{"id":"A74","pred":"mondo_id","subj":"T74","obj":"http://purl.obolibrary.org/obo/MONDO_0005502"},{"id":"A75","pred":"mondo_id","subj":"T75","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"},{"id":"A76","pred":"mondo_id","subj":"T76","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A77","pred":"mondo_id","subj":"T77","obj":"http://purl.obolibrary.org/obo/MONDO_0018661"},{"id":"A78","pred":"mondo_id","subj":"T78","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"},{"id":"A79","pred":"mondo_id","subj":"T79","obj":"http://purl.obolibrary.org/obo/MONDO_0005244"},{"id":"A80","pred":"mondo_id","subj":"T80","obj":"http://purl.obolibrary.org/obo/MONDO_0005108"},{"id":"A81","pred":"mondo_id","subj":"T81","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"},{"id":"A82","pred":"mondo_id","subj":"T82","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A83","pred":"mondo_id","subj":"T83","obj":"http://purl.obolibrary.org/obo/MONDO_0005108"},{"id":"A84","pred":"mondo_id","subj":"T84","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A85","pred":"mondo_id","subj":"T85","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"},{"id":"A86","pred":"mondo_id","subj":"T86","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A87","pred":"mondo_id","subj":"T87","obj":"http://purl.obolibrary.org/obo/MONDO_0020347"},{"id":"A88","pred":"mondo_id","subj":"T88","obj":"http://purl.obolibrary.org/obo/MONDO_0016493"},{"id":"A89","pred":"mondo_id","subj":"T89","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"},{"id":"A90","pred":"mondo_id","subj":"T90","obj":"http://purl.obolibrary.org/obo/MONDO_0005502"},{"id":"A91","pred":"mondo_id","subj":"T91","obj":"http://purl.obolibrary.org/obo/MONDO_0018661"},{"id":"A92","pred":"mondo_id","subj":"T92","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"},{"id":"A93","pred":"mondo_id","subj":"T93","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A94","pred":"mondo_id","subj":"T94","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A95","pred":"mondo_id","subj":"T95","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A96","pred":"mondo_id","subj":"T96","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"}],"text":"The cross-immunity between viral antigens and peripheral nerve glycolipids have not been well-documented. Positive GD1a antibody was reported in a few patients with dengue virus-related GBS (Simon et al., 2016). Anti-ganglioside antibody was not found in patients with COVID-19 and Zika virus-related GBS (Cao-Lormeau et al., 2016). This has led to speculation that the neuropathy in viral infections-related GBS could be due to other autoantibodies that are not detected as yet or the viruses produced nerve damage due to other neurotoxic effects. However, there is paucity of evidence of direct infection of peripheral nerves by viruses from the pathological studies. Good response to immunotherapy in viral infection-related GBS is also against the direct neurotoxic effects of viruses. COVID-19 patients with AIDP responded better as compared to those with axonal variants of GBS; a difference also seen in patients with dengue and Zika virus-related GBS. Recently, a good clinical response in pneumonia has been seen in COVID-19 patients with plasma therapy. Does plasma therapy produce good recovery in COVID-19-related GBS is yet to be seen."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T23","span":{"begin":46,"end":62},"obj":"http://purl.obolibrary.org/obo/UBERON_0001021"},{"id":"T24","span":{"begin":145,"end":146},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T25","span":{"begin":172,"end":177},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T26","span":{"begin":287,"end":292},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T27","span":{"begin":338,"end":341},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T28","span":{"begin":486,"end":493},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T29","span":{"begin":503,"end":508},"obj":"http://purl.obolibrary.org/obo/UBERON_0001021"},{"id":"T30","span":{"begin":621,"end":627},"obj":"http://purl.obolibrary.org/obo/UBERON_0001021"},{"id":"T31","span":{"begin":631,"end":638},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T32","span":{"begin":781,"end":788},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T33","span":{"begin":885,"end":886},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T34","span":{"begin":941,"end":946},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T35","span":{"begin":970,"end":971},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T36","span":{"begin":1008,"end":1011},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T37","span":{"begin":1048,"end":1054},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T38","span":{"begin":1069,"end":1075},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"}],"text":"The cross-immunity between viral antigens and peripheral nerve glycolipids have not been well-documented. Positive GD1a antibody was reported in a few patients with dengue virus-related GBS (Simon et al., 2016). Anti-ganglioside antibody was not found in patients with COVID-19 and Zika virus-related GBS (Cao-Lormeau et al., 2016). This has led to speculation that the neuropathy in viral infections-related GBS could be due to other autoantibodies that are not detected as yet or the viruses produced nerve damage due to other neurotoxic effects. However, there is paucity of evidence of direct infection of peripheral nerves by viruses from the pathological studies. Good response to immunotherapy in viral infection-related GBS is also against the direct neurotoxic effects of viruses. COVID-19 patients with AIDP responded better as compared to those with axonal variants of GBS; a difference also seen in patients with dengue and Zika virus-related GBS. Recently, a good clinical response in pneumonia has been seen in COVID-19 patients with plasma therapy. Does plasma therapy produce good recovery in COVID-19-related GBS is yet to be seen."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T21","span":{"begin":33,"end":41},"obj":"Chemical"},{"id":"T22","span":{"begin":63,"end":74},"obj":"Chemical"},{"id":"T23","span":{"begin":115,"end":119},"obj":"Chemical"},{"id":"T25","span":{"begin":217,"end":228},"obj":"Chemical"}],"attributes":[{"id":"A21","pred":"chebi_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/CHEBI_59132"},{"id":"A22","pred":"chebi_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/CHEBI_33563"},{"id":"A23","pred":"chebi_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/CHEBI_18163"},{"id":"A24","pred":"chebi_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/CHEBI_82607"},{"id":"A25","pred":"chebi_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/CHEBI_28892"}],"text":"The cross-immunity between viral antigens and peripheral nerve glycolipids have not been well-documented. Positive GD1a antibody was reported in a few patients with dengue virus-related GBS (Simon et al., 2016). Anti-ganglioside antibody was not found in patients with COVID-19 and Zika virus-related GBS (Cao-Lormeau et al., 2016). This has led to speculation that the neuropathy in viral infections-related GBS could be due to other autoantibodies that are not detected as yet or the viruses produced nerve damage due to other neurotoxic effects. However, there is paucity of evidence of direct infection of peripheral nerves by viruses from the pathological studies. Good response to immunotherapy in viral infection-related GBS is also against the direct neurotoxic effects of viruses. COVID-19 patients with AIDP responded better as compared to those with axonal variants of GBS; a difference also seen in patients with dengue and Zika virus-related GBS. Recently, a good clinical response in pneumonia has been seen in COVID-19 patients with plasma therapy. Does plasma therapy produce good recovery in COVID-19-related GBS is yet to be seen."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T3","span":{"begin":384,"end":400},"obj":"http://purl.obolibrary.org/obo/GO_0016032"},{"id":"T4","span":{"begin":704,"end":719},"obj":"http://purl.obolibrary.org/obo/GO_0016032"}],"text":"The cross-immunity between viral antigens and peripheral nerve glycolipids have not been well-documented. Positive GD1a antibody was reported in a few patients with dengue virus-related GBS (Simon et al., 2016). Anti-ganglioside antibody was not found in patients with COVID-19 and Zika virus-related GBS (Cao-Lormeau et al., 2016). This has led to speculation that the neuropathy in viral infections-related GBS could be due to other autoantibodies that are not detected as yet or the viruses produced nerve damage due to other neurotoxic effects. However, there is paucity of evidence of direct infection of peripheral nerves by viruses from the pathological studies. Good response to immunotherapy in viral infection-related GBS is also against the direct neurotoxic effects of viruses. COVID-19 patients with AIDP responded better as compared to those with axonal variants of GBS; a difference also seen in patients with dengue and Zika virus-related GBS. Recently, a good clinical response in pneumonia has been seen in COVID-19 patients with plasma therapy. Does plasma therapy produce good recovery in COVID-19-related GBS is yet to be seen."}

{"project":"LitCovid-sentences","denotations":[{"id":"T26","span":{"begin":0,"end":105},"obj":"Sentence"},{"id":"T27","span":{"begin":106,"end":211},"obj":"Sentence"},{"id":"T28","span":{"begin":212,"end":332},"obj":"Sentence"},{"id":"T29","span":{"begin":333,"end":548},"obj":"Sentence"},{"id":"T30","span":{"begin":549,"end":669},"obj":"Sentence"},{"id":"T31","span":{"begin":670,"end":789},"obj":"Sentence"},{"id":"T32","span":{"begin":790,"end":959},"obj":"Sentence"},{"id":"T33","span":{"begin":960,"end":1063},"obj":"Sentence"},{"id":"T34","span":{"begin":1064,"end":1148},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The cross-immunity between viral antigens and peripheral nerve glycolipids have not been well-documented. Positive GD1a antibody was reported in a few patients with dengue virus-related GBS (Simon et al., 2016). Anti-ganglioside antibody was not found in patients with COVID-19 and Zika virus-related GBS (Cao-Lormeau et al., 2016). This has led to speculation that the neuropathy in viral infections-related GBS could be due to other autoantibodies that are not detected as yet or the viruses produced nerve damage due to other neurotoxic effects. However, there is paucity of evidence of direct infection of peripheral nerves by viruses from the pathological studies. Good response to immunotherapy in viral infection-related GBS is also against the direct neurotoxic effects of viruses. COVID-19 patients with AIDP responded better as compared to those with axonal variants of GBS; a difference also seen in patients with dengue and Zika virus-related GBS. Recently, a good clinical response in pneumonia has been seen in COVID-19 patients with plasma therapy. Does plasma therapy produce good recovery in COVID-19-related GBS is yet to be seen."}

{"project":"LitCovid-PD-GlycoEpitope","denotations":[{"id":"T7","span":{"begin":115,"end":119},"obj":"GlycoEpitope"}],"attributes":[{"id":"A7","pred":"glyco_epitope_db_id","subj":"T7","obj":"http://www.glycoepitope.jp/epitopes/EP0056"}],"text":"The cross-immunity between viral antigens and peripheral nerve glycolipids have not been well-documented. Positive GD1a antibody was reported in a few patients with dengue virus-related GBS (Simon et al., 2016). Anti-ganglioside antibody was not found in patients with COVID-19 and Zika virus-related GBS (Cao-Lormeau et al., 2016). This has led to speculation that the neuropathy in viral infections-related GBS could be due to other autoantibodies that are not detected as yet or the viruses produced nerve damage due to other neurotoxic effects. However, there is paucity of evidence of direct infection of peripheral nerves by viruses from the pathological studies. Good response to immunotherapy in viral infection-related GBS is also against the direct neurotoxic effects of viruses. COVID-19 patients with AIDP responded better as compared to those with axonal variants of GBS; a difference also seen in patients with dengue and Zika virus-related GBS. Recently, a good clinical response in pneumonia has been seen in COVID-19 patients with plasma therapy. Does plasma therapy produce good recovery in COVID-19-related GBS is yet to be seen."}